Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYCIDAC-C
- Development stage
- Phase 3
- Lead developer
- Cadila Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
MYCIDAC-C is an active immunotherapy developed by Cadila Pharmaceuticals for the treatment of non-small cell lung cancer (NSCLC), specifically squamous cell carcinoma. The drug consists of a suspension of heat-killed *Mycobacterium w* (also known as *Mycobacterium indicus pranii*), which acts as a Toll-like receptor 2 (TLR2) agonist. By stimulating TLR2, MYCIDAC-C induces a Th1-type cell-mediated immune response. It is the first immunotherapy agent specifically designed to target Desmocollin-3 (DSC-3), a gene frequently expressed in squamous cell lung cancer. Administered via intradermal injection, MYCIDAC-C is typically used in combination with platinum-based chemotherapy doublets to improve overall survival, response rates, and quality of life in patients with advanced NSCLC. It received approval from the Drug Controller General of India (DCGI) and was launched in 2013.
- Brand names
- MYCIDAC-C
- Other names
- Mycobacterium wMycobacterium indicus praniiheat-killed Mycobacterium w
02
Targets
DSC3 (Desmocollin-3)
Beyond the preview
Go deeper on MYCIDAC-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYCIDAC-C.